葵花药业(002737) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥980,317,708.73, representing a 7.31% increase year-over-year[7] - Net profit attributable to shareholders for Q3 2022 was ¥107,852,983.83, up 15.48% compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was ¥100,840,067.15, reflecting a 17.72% increase year-over-year[7] - Total revenue for the third quarter reached ¥3,229,486,011.71, an increase of 7.1% compared to ¥3,015,249,787.60 in the same period last year[27] - Operating profit for the quarter was ¥676,117,380.51, up from ¥461,840,781.33, reflecting a significant growth in profitability[29] - Net profit attributable to shareholders was ¥509,070,636.55, compared to ¥400,698,884.02 in the previous year, marking an increase of 27.1%[29] - Total comprehensive income for the period reached ¥536,667,354.95, an increase from ¥452,603,515.47 in the previous period[32] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,069,591,824.46, an increase of 11.44% from the end of the previous year[7] - Total assets increased to ¥6,069,591,824.46 from ¥5,635,203,544.61, representing a growth of 7.7%[26] - Total liabilities rose to ¥2,031,965,910.63, up from ¥1,700,079,714.65, indicating a 19.5% increase[26] - Non-current liabilities decreased to ¥423,900,656.06 from ¥447,473,643.37, showing a reduction of 5.3%[26] - The company's equity attributable to shareholders increased to ¥3,818,440,313.62 from ¥3,709,407,064.33, reflecting a growth of 2.9%[26] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥781,191,722.90, showing a significant increase of 98.30%[7] - Cash flow from operating activities generated a net amount of ¥781,191,722.90, compared to ¥393,947,375.76 in the previous period, reflecting a significant increase[33] - Cash inflow from investment activities totaled ¥1,693,694,743.41, up from ¥550,736,735.82 in the previous period[36] - Cash outflow for investment activities was ¥2,284,923,425.69, compared to ¥1,342,260,378.97 in the previous period, resulting in a net cash flow from investment activities of -¥591,228,682.28[36] - Cash flow from financing activities resulted in a net outflow of -¥246,516,872.36, compared to -¥154,740,979.24 in the previous period[36] - The ending balance of cash and cash equivalents was ¥1,257,534,070.46, down from ¥1,095,589,385.35 in the previous period[36] Shareholder Information - The basic earnings per share for Q3 2022 was ¥0.19, an increase of 18.75% compared to the same period last year[7] - Basic earnings per share increased to ¥0.88 from ¥0.69, while diluted earnings per share also rose to ¥0.87 from ¥0.69[32] - The major shareholder, Guo Yanbin, reduced his stake in the company by over 1%[16] - The company is actively involved in internal equity structure adjustments among its major shareholders[19] Operational Highlights - The company reported a significant increase in other income, which reached ¥53,815,852.18, up 109.97% from the previous year[12] - The company established a wholly-owned subsidiary as part of its expansion strategy[19] - The company provided guarantees for its controlling subsidiaries, indicating ongoing support for its business operations[19] - Research and development expenses for the quarter were ¥94,784,131.15, slightly down from ¥94,944,223.49, indicating a stable investment in innovation[27] - The total operating costs for the quarter were ¥2,593,122,681.80, an increase from ¥2,538,566,324.06, reflecting a rise in operational expenses[27] Current Assets - As of September 30, 2022, the total current assets amounted to CNY 3,817,636,582.59, an increase from CNY 3,392,928,097.05 at the beginning of the year[20] - The cash and cash equivalents were reported at CNY 1,257,534,070.46, down from CNY 1,320,129,979.45 at the start of the year[20] - The trading financial assets increased significantly to CNY 1,404,000,000.00 from CNY 668,687,524.34[20] - Inventory levels rose to CNY 795,940,189.96 compared to CNY 709,638,552.08 at the beginning of the year[20] - The company reported accounts receivable of CNY 193,095,017.50, slightly down from CNY 194,746,659.98[20]